TW202034945A - 一種人白細胞介素２變體或其衍生物 - Google Patents

一種人白細胞介素２變體或其衍生物 Download PDF

Info

Publication number
TW202034945A
TW202034945A TW108146978A TW108146978A TW202034945A TW 202034945 A TW202034945 A TW 202034945A TW 108146978 A TW108146978 A TW 108146978A TW 108146978 A TW108146978 A TW 108146978A TW 202034945 A TW202034945 A TW 202034945A
Authority
TW
Taiwan
Prior art keywords
variant
seq
derivative
scope
patent application
Prior art date
Application number
TW108146978A
Other languages
English (en)
Chinese (zh)
Inventor
陳磊
胡齊悅
葛虎
林�源
王宏偉
歐陽超
孔祥林
廖成
張連山
Original Assignee
大陸商江蘇恆瑞醫藥股份有限公司
大陸商上海恆瑞醫藥有限公司
大陸商上海盛迪醫藥有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 大陸商江蘇恆瑞醫藥股份有限公司, 大陸商上海恆瑞醫藥有限公司, 大陸商上海盛迪醫藥有限公司 filed Critical 大陸商江蘇恆瑞醫藥股份有限公司
Publication of TW202034945A publication Critical patent/TW202034945A/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
TW108146978A 2018-12-21 2019-12-20 一種人白細胞介素２變體或其衍生物 TW202034945A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN201811570930.5 2018-12-21
CN201811570930 2018-12-21
CN201910158957 2019-03-04
CN201910158957.1 2019-03-04

Publications (1)

Publication Number Publication Date
TW202034945A true TW202034945A (zh) 2020-10-01

Family

ID=71102517

Family Applications (1)

Application Number Title Priority Date Filing Date
TW108146978A TW202034945A (zh) 2018-12-21 2019-12-20 一種人白細胞介素２變體或其衍生物

Country Status (13)

Country Link
US (1) US20220056094A1 (fr)
EP (1) EP3875475A4 (fr)
JP (1) JP7543269B2 (fr)
KR (1) KR20210107714A (fr)
CN (1) CN113383013B (fr)
AU (1) AU2019409196A1 (fr)
BR (1) BR112021010983A2 (fr)
CA (1) CA3123471A1 (fr)
MX (1) MX2021007085A (fr)
MY (1) MY205914A (fr)
TW (1) TW202034945A (fr)
WO (1) WO2020125743A1 (fr)
ZA (1) ZA202103785B (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021102063A1 (fr) 2019-11-20 2021-05-27 Anwita Biosciences, Inc. Protéines de fusion de cytokine, leurs compositions pharmaceutiques et leurs applications thérapeutiques
WO2021222150A2 (fr) 2020-04-28 2021-11-04 Anwita Biosciences, Inc. Polypeptides d'interleukine-2 et protéines de fusion de ceux-ci, ainsi que leurs compositions pharmaceutiques et leurs applications thérapeutiques
CN116323653A (zh) 2020-09-04 2023-06-23 山东先声生物制药有限公司 Il-2突变体及其应用
CN114380919B (zh) * 2020-10-18 2024-06-25 北京志道生物科技有限公司 经修饰的il-2分子及其用途
CA3201446A1 (fr) * 2020-11-13 2022-05-19 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Composition pharmaceutique comprenant un variant d'interleukine 2 humaine ou un derive de celle-ci et son utilisation
WO2023281485A1 (fr) 2021-07-09 2023-01-12 Bright Peak Therapeutics Ag Polypeptides il-2 modifiés pour le traitement de maladies inflammatoires et auto-immunes
CN113831402A (zh) * 2021-07-30 2021-12-24 西安龙腾景云生物科技有限公司 一种人白细胞介素2变体及其用途
JP7618848B2 (ja) * 2021-07-30 2025-01-21 ドラコターピン バイオメディスン エルエルシー ヒトインターロイキン－２変異体およびその使用
JP2024536840A (ja) * 2021-09-26 2024-10-08 ウーシー バイオロジクス アイルランド リミテッド Ｉｌ－２バリアント及びその融合タンパク質
MX2024009715A (es) 2022-02-11 2024-08-19 Jiangsu Hengrui Pharmaceuticals Co Ltd Inmunoconjugado y su uso del mismo.
EP4499846A1 (fr) 2022-03-25 2025-02-05 Universität Zürich Ciblage induit par adenovirus de cellules immunitaires activees
TWI875131B (zh) * 2022-08-16 2025-03-01 國立陽明交通大學 介白素-2變異體及其於治療癌症的用途
CN115850436B (zh) * 2022-10-14 2026-02-03 海徕科(北京)生物技术有限公司 白介素2突变体及其应用
WO2024083097A1 (fr) * 2022-10-19 2024-04-25 北京志道生物科技有限公司 Mutant d'il-2
CN116041539B (zh) * 2022-10-31 2023-07-21 山东博安生物技术股份有限公司 Il-2突变体免疫缀合物
WO2024146575A1 (fr) * 2023-01-04 2024-07-11 北京晶泰科技有限公司 Variant d'interleukine-2 et son utilisation
KR20260054696A (ko) 2023-08-16 2026-04-22 상하이 맙젠 바이오텍 리미티드 면역접합체를 포함하는 약학적 조성물 및 이의 용도

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60502136A (ja) * 1983-08-10 1985-12-12 アムジエン　インコーポレイテツド 微生物によるインタ−ル−キン２の形質発現
WO1985000817A1 (fr) * 1983-08-10 1985-02-28 Amgen Expression microbienne de l'interleukine ii
DZ2788A1 (fr) 1998-05-15 2003-12-01 Bayer Ag Agonistes et antagonistes selectifs à IL-2.
WO2003015697A2 (fr) 2001-08-13 2003-02-27 University Of Southern California Mutants d'interleukine-2 a toxicite reduite
ATE542137T1 (de) * 2001-12-04 2012-02-15 Merck Patent Gmbh Immunocytokine mit modulierter selektivität
WO2005007121A2 (fr) * 2003-07-18 2005-01-27 Massachusetts Institute Of Technology Polypeptides de l'interleukine-2(il-2) mutante
EP1723251A4 (fr) * 2004-03-05 2008-04-23 Novartis Vaccines & Diagnostic Systeme de tests in vitro permettant de predire la tolerabilite d'agents therapeutiques chez des patients
GB2415904B (en) * 2005-02-07 2006-10-25 Chiron Corp Preparing aldesleukin for pharmaceutical use
US8906356B2 (en) 2007-11-05 2014-12-09 Massachusetts Institute Of Technology Mutant interleukin-2 (IL-2) polypeptides
DE102008023820A1 (de) 2008-05-08 2009-11-12 Aicuris Gmbh & Co. Kg Mittel zur Behandlung und/oder Prophylaxe einer Autoimmunerkrankung und zur Bildung von Regulatorischen T-Zellen
US20110274650A1 (en) 2009-01-21 2011-11-10 Amgen Inc. Compositions and methods of treating inflammatory and autoimmune diseases
CU23923B1 (es) 2010-11-12 2013-07-31 Ct De Inmunología Molecular Polipéptidos derivados de la il-2 con actividad agonista
HUE029139T2 (hu) * 2011-02-10 2017-02-28 Roche Glycart Ag Mutáns interleukin-2 polipeptidek
WO2016014428A2 (fr) * 2014-07-21 2016-01-28 Delinia, Inc. Molécules qui activent sélectivement les cellules t régulatrices pour le traitement de maladies auto-immunes
WO2017136818A2 (fr) 2016-02-05 2017-08-10 Washington University Compositions et méthodes pour l'administration ciblée de cytokines
AU2018273914A1 (en) * 2017-05-24 2019-11-14 Pandion Operations, Inc. Targeted immunotolerance

Also Published As

Publication number Publication date
CA3123471A1 (fr) 2020-06-25
US20220056094A1 (en) 2022-02-24
EP3875475A1 (fr) 2021-09-08
ZA202103785B (en) 2022-07-27
JP7543269B2 (ja) 2024-09-02
WO2020125743A1 (fr) 2020-06-25
CN113383013A (zh) 2021-09-10
MY205914A (en) 2024-11-20
MX2021007085A (es) 2021-08-11
JP2022513265A (ja) 2022-02-07
AU2019409196A1 (en) 2021-06-17
EP3875475A4 (fr) 2022-12-07
CN113383013B (zh) 2022-11-04
BR112021010983A2 (pt) 2021-08-31
KR20210107714A (ko) 2021-09-01

Similar Documents

Publication Publication Date Title
JP7543269B2 (ja) ヒトインターロイキン２の変異体またはその誘導体
CN111647068A (zh) 一种人白细胞介素2变体或其衍生物
EP2467165B1 (fr) Immunoconjugués ciblés
WO2018127610A1 (fr) Agonistes conditionnels de réponses immunitaires
WO2020228791A1 (fr) Cellules immunitaires à prolifération de protéine mutante il-2
CN113667004B (zh) 一种白介素2突变体
US20220008526A1 (en) Methods and compositions for cancer immunotherapy
CN122036911A (zh) 一种人白细胞介素2变体及其用途
WO2020108426A1 (fr) Variant d'interleukine 10 humaine et dérivé correspondant
JP2025066741A (ja) ヒトインターロイキン－２変異体およびその使用
RU2799437C2 (ru) Вариант человеческого интерлейкина-2 или его производное
WO2023169349A1 (fr) Protéine de fusion, procédé de préparation et utilisation associés
KR20190095943A (ko) 고갈 활성을 갖는 인간화 cxcr3 항체 및 이의 사용 방법
HK40051456A (en) Human interleukin-2 variant or derivative thereof
HK40051456B (en) Human interleukin-2 variant or derivative thereof
CN116178572B (zh) 构建嵌合蛋白的嵌合区域、构建方法、嵌合蛋白及其应用
WO2025251928A1 (fr) VARIANTS D'IL2Rβ MODIFIÉS ET LEURS PROCÉDÉS D'UTILISATION
HK40105603A (en) Human interleukin-2 variant and use thereof
BR122025013056A2 (pt) Variante de interleucina-2 humana e uso da mesma
HK40057771A (en) Il-2 mutant protein proliferating immune cells